The Clinical Research Of CHD SAP With GuanXinDanShen Capsules And Enhanced External Counterpulsation Combination Therapy

Objective:For guiding Clinical Application,the research was designed to evaluate the efficiency and safety of GuanXinDanShen Capsules And Enhanced External Counterpulsation Combination therapy,in the treatment of CHD SAP with the identification of blood stagnates in collateral of heart.Methods:Sixty CHD SAP patients which belong to the identification of blood stagnates in collateral of heart were enrolled and divided into two groups, according to the random trial method.Based on the common western medicine treatment,the patients of therapeutic group(30 cases) were given GuanXinDanShen Capsules and EECP Combination therapy,and the patients of control group(30 cases) were given GuanXinDanShen Capsules.After four weeks treament course,we observed the curative effects of angina pectoris,syndromes of Traditional Chinese Medicine(TCM),ECG,VAS and SAQ scores,Hemorrheology,etc.Results:A total of 60 patients constituted our study sample.Baseline data of the therapeutic group and the control group were comparable(P>0.05).1,The improvement of angina pectoris symptoms:At the end-point,the symptoms of angina pectoris were significantly improved,and angina pectoris scores reduced,in both of two groups(P<0.01).And there was significant difference of angina pectoris degree between two groups(P<0.01).2,The improvement of TCM symptoms:After treatment course,the symptoms of TCM were significantly improved,and TCM scores reduced,in both of two groups(P<0.01).And there was significant difference of TCM degree between two groups at the end-point(P<0.01).3,The improvement of ECG:Compared with control group,the total efficient of ECG was higher in therapeutic group at the end-point,but there was no significant difference(P>0.05). 4,The decrease of nitroglycerin consumption:After treatment course,the nitroglycerin consumption was significantly decreased,in both of two groups(P<0.01).The decrease rate of nitroglycerin of the therapeutic group was superior to the control group at the end-point(P<0.05).5,VAS scores:After treatment course,VAS scores were significantly reduced, in both of two groups(P<0.01).Compared with the control group,the efficient of VAS was better in the therapeutic group at the end-point,and there was significant difference(P<0.01).6,SAQ scores:After treatment course,SAQ scores were significantly reduced,and the quality of life(QOL) was improved,in both of two groups (P<0.01).Compared with the control group,the improvement of QOL was better in the therapeutic group at the end-point(P<0.01).7,Hemorrheology:In the therapeutic group,the value of nb(200/s),ηb(3/s), HRV,LRV and np were significantly decreased at the end-point(P<0.01 or P<0.05).The value of ESR was decreased,but there was no significant difference(P>0.05).In the control group,the value of nb(200/s) andηb(3/s) were significantly decreased(P<0.05).The others were decreased, but there were no significant difference(P>0.05).In the therapeutic group, the efficient of nb(200/s),HRV,LRV andηp were superior to the control group at the end-point(P<0.01 or P<0.05).But there were no significant difference(P>0.05) in the remaining two hemorrheology indicators.8,Safety:There was no significant difference about safty between two groups.And there were no serious adverse reactions at the end-point.The treatments are safe.Conclusion:GuanXinDanShen Capsules And EECP Combination therapy is exactly effective and safe for the treatment on CHD SAP patients with the identification of blood stagnates in collateral of heart.It can improve angina pectoris symptoms,TCM symptoms and the quality of life,reduce the amount of nitroglycerin,and improve the hemorrheology indicators.It could be served as a good clinical joint approach.